Protagonist Therapeutics (PTGX) Other Non-Current Liabilities (2015 - 2021)
Protagonist Therapeutics (PTGX) reported Other Non-Current Liabilities of $121000.0 for Q3 2021, down 28.82% on a YoY basis from $170000.0 in Q3 2020, and little changed sequentially from $121000.0 in Q2 2021.
Protagonist Therapeutics (PTGX) Other Non-Current Liabilities (2015 - 2021) Analysis & Trends
Protagonist Therapeutics (PTGX) has 3 years of Other Non-Current Liabilities data on file, last reported at $121000.0 in Q3 2021.
- For the quarter ending Q3 2021, Other Non-Current Liabilities fell 28.82% year-over-year to $121000.0; the trailing twelve-month figure through Sep 2021 stood at $121000.0 (down 28.82% YoY), and the FY2020 full-year result was $121000.0, changed N/A from the prior year.
- Other Non-Current Liabilities steadied at $121000.0 in Q3 2021, from $121000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $170000.0 in Q3 2020 to a low of $92000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 121,000.00 |
| Jun 30, 2021 | 121,000.00 |
| Mar 31, 2021 | 121,000.00 |
| Dec 31, 2020 | 121,000.00 |
| Sep 30, 2020 | 170,000.00 |
| Jun 30, 2020 | 92,000.00 |
| Dec 31, 2015 | 2.12 Mn |